Zn(II) is an inhibitor of SARS-CoV-2 ′s RNA-dependent RNA polymerase, and chloroquine and hydroxychloroquine are Zn(II) ionophores–this statement gives a curious mind a lot to think about. We show results of the first clinical trials on chloroquine (CQ) and hydroxychloroquine (HCQ) in the treatment of COVID-19, as well as earlier reports on the anticoronaviral properties of these two compounds and of Zn(II) itself. Other FDA-approved Zn(II) ionophores are given a decent amount of attention and are thought of as possible COVID-19 therapeutics.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, Chloroquine, 2019-nCoV, Zn(II) ionophores, hydroxy- chloroquine, 【초록키워드】 Treatment, clinical trial, Hydroxychloroquine, COVID-19 therapeutics, RNA-dependent RNA polymerase, HCQ, inhibitor, Other, Compound, thought,
【저자키워드】 COVID-19, SARS-CoV-2, Chloroquine, 2019-nCoV, Zn(II) ionophores, hydroxy- chloroquine, 【초록키워드】 Treatment, clinical trial, Hydroxychloroquine, COVID-19 therapeutics, RNA-dependent RNA polymerase, HCQ, inhibitor, Other, Compound, thought,